Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology

Volumn 59, Issue 4, 2008, Pages 569-576

  Pariser, David ^a   Loss, Robert ^b   Jarratt, Michael ^c   Abramovits, William ^d   Spencer, James ^e   Geronemus, Roy ^f   Bailin, Philip ^g   Bruce, Suzanne ^h  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Dermatology Associates of Rochester   (United States)

^c DermResearch Inc   (United States)

^d Texas Dermatology Research Institute Dallas   (United States)

^e Spencer Dermatology and Skin Surgery Center   (United States)

^f Laser and Skin Surgery Center

^g LERNER RESEARCH INSTITUTE   (United States)

^h Suzanne Bruce and Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; PLACEBO;

ABDOMINAL PAIN; ACTINIC KERATOSIS; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BLISTER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHEMA; FEMALE; GALLSTONE; HUMAN; ILLUMINATION; LIGHT EMITTING DIODE; MALE; MULTICENTER STUDY; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RED LIGHT; SKIN BURNING SENSATION; SKIN DISCOMFORT; SKIN EXFOLIATION; SKIN PAIN; SMALL CELL CARCINOMA;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; DOUBLE-BLIND METHOD; FACIAL DERMATOSES; FEMALE; HUMANS; KERATOSIS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SCALP DERMATOSES; TREATMENT OUTCOME;

EID: 51349131325     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.05.031     Document Type: Article

References (22)

1. Salasche S.J. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 42 (2000) 4-7
2. Moy R.L. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 42 (2000) 8-10
3. Memon A.A., Tomenson J.A., Bothwell J., and Friedmanm P.S. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142 (2000) 1154-1159
4. Stockfleth E., and Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 16 (2006) 599-606
5. Hsi R.A., Rosenthal D.I., and Glatstein E. Photodynamic therapy in the treatment of cancer. Drugs 57 (1999) 725-734
6. Angell-Petersen E., Sorensen R., Warloe T., Soler A.M., Moan J., Peng Q., et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 126 (2006) 265-271
7. Braathen L.R., Szeimies R.-M., Basset-Seguin N., Bissonnette R., Foley P., Pariser D., et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 56 (2007) 125-143
8. Peng Q., Moan J., Warloe T., Iani V., Steen H.B., Bjorseth A., et al. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 34 (1996) 95-96
9. Kloek J. Beijersbergen van Henegouwen GMJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 64 (1996) 994-1000
10. Fritsch C., Homey B., Stahl W., Lehmann P., Ruzicka T., and Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of 5-aminolevulinic acid methylester. Photochem Photobiol 68 (1998) 218-221
11. Pariser D.M., Lowe N.J., Stewart D.M., Jarrat M.T., Lucky A.W., Pariser R.J., et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results from a prospective randomized multicenter trial. J Am Acad Dermatol 48 (2003) 227-232
12. Freeman M., Vinciullo C., Francis D., Spelman L., Nguyen R., Fergin P., et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle of cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat 14 (2003) 99-106
13. Szeimies R.M., Karrer S., Radakovic-Fijan S., Tanew A., Calzavara-Pinton P.G., Zane C., et al. Photodynamic therapy using topical methyl-5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 47 (2002) 258-262
14. Morton C., Campbell S., Gupta G., Keohane S., Lear J., Zaki I., et al. Intraindividual, right-left comparison of topical methyl aminolevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicenter, randomized, controlled study. Br J Dermatol 155 (2006) 1029-1036
15. Olsen E.A., Abernethy L., Kulp-Shorten C., Callen J.P., Glazer S.D., Huntley A., et al. A double-blind vehicle controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 24 (1991) 738-743
16. Clopper C., and Pearson S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26 (1934) 404-413
17. Morton C.A. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin 25 (2007) 81-87
18. Tarstedt M., Rosdahl I., Berne B., Svanberg K., and Wennberg A.M. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 85 (2005) 424-428
19. Kurwa H.A., Yong-Gee S.A., Seed P.T., Markey A.C., and Barlow R.J. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 41 (1999) 414-418
20. Jorizzo J., Dinehart S., Matheson R., Moore J.K., Ling M., Fox T.L., et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 57 (2007) 265-268
21. Alomar A., Bichel J., and McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 157 (2007) 133-141
22. Lebwohl M., Dinehart S., Whiting D., Lee P.K., Tawfik N., Jorizzo J., et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50 (2004) 714-721